Insider Selling: Twist Bioscience Co. (NASDAQ:TWST) SVP Sells 1,057 Shares of Stock

Twist Bioscience Co. (NASDAQ:TWST) SVP Paula Green sold 1,057 shares of the company’s stock in a transaction that occurred on Monday, November 4th. The shares were sold at an average price of $41.56, for a total value of $43,928.92. Following the transaction, the senior vice president now directly owns 121,013 shares of the company’s stock, valued at $5,029,300.28. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Paula Green also recently made the following trade(s):

• On Wednesday, October 2nd, Paula Green sold 3,310 shares of Twist Bioscience stock. The shares were sold at an average price of $43.21, for a total value of $143,025.10.
• On Friday, September 20th, Paula Green sold 297 shares of Twist Bioscience stock. The shares were sold at an average price of $46.94, for a total value of $13,941.18.

Twist Bioscience Trading Up 5.3 %

Shares of TWST opened at $45.42 on Thursday. The business’s fifty day simple moving average is $43.64 and its two-hundred day simple moving average is $45.43. Twist Bioscience Co. has a 12 month low of $15.85 and a 12 month high of $60.90. The company has a market cap of $2.66 billion, a price-to-earnings ratio of -11.89 and a beta of 1.78.

Hedge Funds Weigh In On Twist Bioscience

Hedge funds and other institutional investors have recently modified their holdings of the company. BNP Paribas Financial Markets lifted its holdings in shares of Twist Bioscience by 34.8% during the 1st quarter. BNP Paribas Financial Markets now owns 171,823 shares of the company’s stock valued at $5,895,000 after buying an additional 44,349 shares during the period. SageView Advisory Group LLC bought a new position in shares of Twist Bioscience during the 1st quarter valued at $1,144,000. Susquehanna Fundamental Investments LLC bought a new position in shares of Twist Bioscience during the 1st quarter valued at $300,000. Sei Investments Co. lifted its holdings in shares of Twist Bioscience by 32.7% during the 1st quarter. Sei Investments Co. now owns 223,555 shares of the company’s stock valued at $7,670,000 after buying an additional 55,124 shares during the period. Finally, Silvercrest Asset Management Group LLC raised its holdings in Twist Bioscience by 38.6% in the 1st quarter. Silvercrest Asset Management Group LLC now owns 134,215 shares of the company’s stock worth $4,605,000 after purchasing an additional 37,376 shares during the period.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on TWST shares. JPMorgan Chase & Co. upped their target price on Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a report on Monday, August 5th. Robert W. Baird upped their target price on Twist Bioscience from $40.00 to $46.00 and gave the stock an “outperform” rating in a report on Monday, August 5th. Barclays reduced their target price on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating on the stock in a report on Monday, August 5th. Leerink Partners upped their target price on Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a report on Thursday, October 17th. Finally, Evercore ISI upped their price target on Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. One analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $51.22.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.